Prof. Dr Ebersbach highlights the burden of motor fluctuations in patients with Parkinson’s disease treated with long-term levodopa therapy.1–10 Current strategies for treating motor fluctuations, including COMT inhibitors such as opicapone are also discussed.11,12,15,161/3 Next Interview
Prof. Dr Ebersbach discusses the results of a post hoc analysis of the BIPARK-I and -II studies,13,14 which investigated the efficacy and safety of the COMT inhibitor, opicapone on motor fluctuations in Parkinson’s disease. Key methods and results to determine the effect of opicapone based on disease duration and level of levodopa therapy are highlighted.2/3 Next Interview
Dr Kurtis discusses the implications of the BIPARK-I and -II post hoc analysis including patient selection considerations,11,17–19 outstanding questions in the role of opicapone in the treatment of motor fluctuations20 and unmet needs that remain in Parkinson’s disease in general.21,223/3 Leave Feedback
Learning Objectives & Overview
Patients with Parkinson’s disease treated long-term with levodopa develop OFF periods characterised by motor fluctuations,1–4 which decreases health-related quality of life for patients and care partners.5–10 The once-daily COMT inhibitor, opicapone, increases the bioavailability of levodopa, leading to a more continuous delivery11,12 . In the BIPARK-I and -II studies opicapone decreased OFF-time and increased ON-time.13,14 We interviewed one of the authors of a recent post hoc analysis of the BIPARK-I and -II studies13,14 on the key methods and results to determine the impact of opicapone across the motor fluctuation spectrum, in addition to a leading expert on the wider implications of the results for patients.
After watching this activity, participants should be better able to:
- Recognise the burden of motor fluctuations in Parkinson’s disease and the need to optimise treatment to ensure the best possible disease outcomes.
- Describe the key results from the post hoc analysis of the BIPARK studies including the efficacy of opicapone throughout the entire spectrum of motor fluctuations.
- Understand the implications of these results for clinical practice, including the potential for early intervention on motor fluctuations in PD.
- Fackrell R, et al. Neurodegener Dis Manag. 2018;8(5):349-360.
- Katzenschlager R, et al. Neurology. 2008;71(7):474-80.
- Verschuur CVM, et al. N Engl J Med. 2019;380(4):315-324.
- Olanow CW, et al. Lancet Neurol. 2006;5(8):677-87.
- Stocchi F, et al. Parkinsonism Relat Disord. 2014;20(2):204-211.
- Chapuis S, et al. Mov Disord 2005; 20(2): 224-30.
- Rascol O, et al. J Neural Transm (Vienna) 2015. 122(10): 1447-55.
- Grimbergen YA, et al. J Parkinsons Dis 2013; 3(3): 409-13.
- Mosley PE, et al. J Geriatr Psychiatry Neurol 2017; 30(5): 235-52.
- Onozawa R, et al. J Neurol Sci 2016; 364: 1-5.
- EMA 2016. Available at: https://www.ema.europa.eu/en/documents/product-information/ongentys-epar-product-information_en.pdf (accessed September 2021).
- Stocchi F, et al. Eur Neurol. 2010;63(5):257-66.
- Ferreira JJ, et al. Lancet Neurol. 2016;15(2):154-165.
- Lees AJ, et al. JAMA Neurol. 2017;74(2):197-206.
- Pahwa R, Lyons KE. Curr Med Res Opin. 2009;25(4):841-9.
- Konta B, Frank W. GMS Health Technol Assess. 2008;4:Doc05.
- Han JW, et al. J Korean Med Sci. 2018;33(47):e300.
- Meder D, et al. Neuroimage. 2019;190:79-93.
- Zhu K, et al. Parkinsonism Relat Disord. 2016;33:51-57.
- Osig C, et al. J Neural Transm (Vienna). 2016;123(1):57-64.
- Rukavina K et al. Expert Rev Neurother. 2021;21(3):335-352.
- Sharpe G, et al. Front Neurol. 2020;11:576569.